- Dr Omar Abu Abed
Dr Omar Abu Abed
Dr Omar Abu Abed
Faculty: Pharmacy and medical sciences
Specialization: Drug delivery systems and nanomedicine
FRQ Research Area: Health Sciences
Host university: National Institute of Scientific Research, Quebec
Host Department: Energy, Materials, and Telecommunications Centre.
Canadian Partner: Prof Marc A. Gauthier
Research Domain: Biopharmaceuticals
Research Project Title: Design and Evaluation of a Therapeutic Protein nano-formulation
Research Project Purpose: Pancreatic adenocarcinoma remains one of the most common causes of cancer-related mortality, especially with its invasive nature against the body and poor patient prognosis due to the failure of the available chemotherapeutic options. Fortunately, it was proven that some of the tumour necrosis factor ligands (proteins) might selectively kill pancreatic cancer cells. However, the lack of selectivity, specificity, and the prolongation at the target site decrease its potential roles and clinical applications. Also, the innate unstable nature of proteins may burden the formulators with more challenges to overcome during the process of handling proteins. Therefore, there is an urgent need to develop a novel therapeutic approach to targeting, localising and protecting the therapeutic interaction between the proteins and the cancer cells. Targeted delivery systems combining efficient therapeutic functionality via the delivery of apoptotic proteins are emerging as the next generation of theranostic nanomedicine with great promise for prospective clinical applications. The proposed project aims at the development of biocompatible nanoparticles that can selectively target pancreatic cancer cells to deliver efficiently therapeutic proteins and enhance their internalisation in cells of interest.
Expected Results: The development of sTRAIL-nanoparticles based approach for pancreatic cancer cells is expected to have a direct positive impact on the initiation of alternative and potentially more effective treatments of pancreas cancer by eradicating both whole cancer and tumour initiating fractions while avoiding undesirable side effects associated with ineffective chemotherapeutic drugs.